Drugs / Epoetin Alfa (EPO)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00715364 | Aug 2009 → Jun 2010 | ischemic stroke | Stem Cell Therapeutics Corp. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epoetin Alfa (EPO) | “A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients” NCT00715364 ↗ |
| Known as | rEPO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00715364 ↗ |
| Route | Intravenous | “rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation” NCT00715364 ↗ |